K Sandy Pang

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2721911/publications.pdf

Version: 2024-02-01

234 papers	7,918 citations	53939 47 h-index	81351 76 g-index
236 all docs	236 docs citations	236 times ranked	5858 citing authors

#	Article	IF	Citations
1	In Defense of Current Concepts and Applications of Clearance in Drug Development and Therapeutics. Drug Metabolism and Disposition, 2022, 50, 187-190.	1.7	9
2	Hepatic clearance models and IVIVE predictions. Clinical Pharmacology and Therapeutics, 2022, 111, 1205-1207.	2.3	5
3	Significance of the Vitamin D Receptor on Crosstalk with Nuclear Receptors and Regulation of Enzymes and Transporters. AAPS Journal, 2022, 24, .	2.2	10
4	Impact of age, hypercholesterolemia, and the vitamin D receptor on brain endogenous Î²â€amyloid peptide accumulation in mice. Biopharmaceutics and Drug Disposition, 2021, 42, 372-388.	1.1	6
5	Measuring Amyloidâ€Î² Peptide Concentrations in Murine Brain with Improved ELISA Assay. Current Protocols, 2021, 1, e253.	1.3	1
6	Current Evidence and Future Directions of Tranexamic Acid Use, Efficacy, and Dosing for Major Surgical Procedures. Journal of Cardiothoracic and Vascular Anesthesia, 2020, 34, 782-790.	0.6	20
7	Human Amyloid-Î²₄₀ Kinetics after Intravenous and Intracerebroventricular Injections and Calcitriol Treatment in Rats In Vivo. Drug Metabolism and Disposition, 2020, 48, 944-955.	1.7	5
8	Noteworthy idiosyncrasies of 1Î±,25â€dihydroxyvitamin D3kinetics for extrapolation from mouse to man: Commentary. Biopharmaceutics and Drug Disposition, 2020, 41, 126-148.	1.1	5
9	The Segregated Intestinal Flow Model (SFM) for Drug Absorption and Drug Metabolism: Implications on Intestinal and Liver Metabolism and Drugâ€“Drug Interactions. Pharmaceutics, 2020, 12, 312.	2.0	10
10	Hepatic clearance concepts and misconceptions: Why the well-stirred model is still used even though it is not physiologic reality?. Biochemical Pharmacology, 2019, 169, 113596.	2.0	43
11	Theoretical consideration of the properties of intestinal flow models on routeâ€dependent drug removal: Segregated Flow (SFM) vs. Traditional (TM). Biopharmaceutics and Drug Disposition, 2019, 40, 195-213.	1.1	7
12	To the Editor. Anesthesia and Analgesia, 2019, 128, e125-e126.	1.1	3
13	Potencies of vitamin D analogs, 1Î±â€hydroxyvitamin D₃, 1Î±â€hydroxyvitamin D₂ and 25â€hydroxyvitamin D₃, in lowering cholesterol in hypercholesterolemic mice in vivo. Biopharmaceutics and Drug Disposition, 2018, 39, 196-204.	1.1	9
14	Tranexamic Acid Dosing for Cardiac Surgical Patients With Chronic Renal Dysfunction: A New Dosing Regimen. Anesthesia and Analgesia, 2018, 127, 1323-1332.	1.1	56
15	Highlighting Vitamin D Receptorâ€Targeted Activities of 1Î±,25-Dihydroxyvitamin D3in Mice via Physiologically Based Pharmacokinetic-Pharmacodynamic Modeling. Drug Metabolism and Disposition, 2018, 46, 75-87.	1.7	12
16	Alterations in gene expression in vitamin Dâ€deficiency: Downâ€regulation of liver Cyp7a1 and renal Oat3 in mice. Biopharmaceutics and Drug Disposition, 2018, 39, 99-115.	1.1	11
17	Commentary on â€œThe Universally Unrecognized Assumption in Predicting Drug Clearance and Organ Extraction Ratioâ€. Clinical Pharmacology and Therapeutics, 2018, 103, 386-388.	2.3	19
18	Finding T_{max} and C_{max} in Multicompartmental Models. Drug Metabolism and Disposition, 2018, 46, 1796-1804.	1.7	10

#	Article	IF	Citations
19	Strategies and limitations associated with in vitro characterization of vitamin D receptor activators. Biochemical Pharmacology, 2018, 155, 547-561.	2.0	1
20	Comparing early liver graft function from heart beating and livingâ€donors: A pilot study aiming to identify new biomarkers of liver injury. Biopharmaceutics and Drug Disposition, 2017, 38, 326-339.	1.1	11
21	Professor Yuichi Sugiyama: A Brilliant, Creative, Amicable, Charming, and Humorous Pharmaceutical Scientist. Journal of Pharmaceutical Sciences, 2017, 106, 2188-2194.	1.6	0
22	Revisiting the role of gut wall in the fate of orally administered drugs: Why now and to what effect?. Biopharmaceutics and Drug Disposition, 2017, 38, 87-93.	1.1	3
23	Unequivocal evidence supporting the segregated flow intestinal model that discriminates intestine versus liver firstâ€pass removal with PBPK modeling. Biopharmaceutics and Drug Disposition, 2017, 38, 231-250.	1.1	7
24	Physiologically based pharmacokinetic modeling revealed minimal codeine intestinal metabolism in firstâ€pass removal in rats. Biopharmaceutics and Drug Disposition, 2017, 38, 50-74.	1.1	5
25	Disrupted Murine Gutâ€“toâ€“Human Liver Signaling Alters Bile Acid Homeostasis in Humanized Mouse Liver Models. Journal of Pharmacology and Experimental Therapeutics, 2017, 360, 174-191.	1.3	23
26	Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice. Journal of Visualized Experiments, 2017, , .	0.2	4
27	PBPK Modeling to Estimate Metabolite Formation From First-Pass Organs: Intestine and Liver. , 2017, , 83-101.		1
28	Functional Integrity of the Chimeric (Humanized) Mouse Liver: Enzyme Zonation, Physiologic Spaces, and Hepatic Enzymes and Transporters. Drug Metabolism and Disposition, 2016, 44, 1524-1535.	1.7	12
29	Metabolite Kinetics: The Segregated Flow Model for Intestinal and Whole Body Physiologically Based Pharmacokinetic Modeling to Describe Intestinal and Hepatic Glucuronidation of Morphine in Rats In Vivo. Drug Metabolism and Disposition, 2016, 44, 1123-1138.	1.7	15
30	Polymerâ€“lipid hybrid nanoparticles synchronize pharmacokinetics of co-encapsulated doxorubicinâ€“mitomycin C and enable their spatiotemporal co-delivery and local bioavailability in breast tumor. Nanomedicine: Nanotechnology, Biology, and Medicine, 2016, 12, 1279-1290.	1.7	78
31	Physiologically-Based Pharmacokinetic-Pharmacodynamic Modeling of 1Â,25-Dihydroxyvitamin D3 in Mice. Drug Metabolism and Disposition, 2016, 44, 189-208.	1.7	13
32	Dealing with the complex drugâ€“drug interactions: Towards mechanistic models. Biopharmaceutics and Drug Disposition, 2015, 36, 71-92.	1.1	58
33	Pharmacokinetic modeling of tranexamic acid for patients undergoing cardiac surgery with normal renal function and model simulations for patients with renal impairment. Biopharmaceutics and Drug Disposition, 2015, 36, 294-307.	1.1	24
34	<scp>PKPD</scp> modelling to predict altered disposition of 1Î±,25â€dihydroxyvitamin <scp>D</scp>₃ in mice due to doseâ€dependent regulation of <scp>CYP27B1</scp> on synthesis and <scp>CYP24A1</scp> on degradation. British Journal of Pharmacology, 2015, 172, 3611-3626.	2.7	6
35	PBPK Modeling to Unravel Nonlinear Pharmacokinetics of Verapamil to Estimate the Fractional Clearance for Verapamil N-Demethylation in the Recirculating Rat Liver Preparation. Drug Metabolism and Disposition, 2015, 43, 631-645.	1.7	8
36	Response to Letter to the Editor on â€œFractional Clearance for Verapamil N-Demethylation in the Isolated Rat Liver Preparationâ€. Drug Metabolism and Disposition, 2015, 43, 1058-1059.	1.7	1

#	Article	IF	Citations
37	Vitamin D Receptor Activation Induces P-Glycoprotein and Increases Brain Efflux of Quinidine:An Intracerebral Microdialysis Study in Conscious Rats. Pharmaceutical Research, 2015, 32, 1128-1140.	1.7	23
38	Effects of 1Î±,25-Dihydroxyvitamin D 3 , the Natural Vitamin D Receptor Ligand, on the Pharmacokinetics of Cefdinir and Cefadroxil, Organic Anion Transporter Substrates, in Rat. Journal of Pharmaceutical Sciences, 2014, 103, 3793-3805.	1.6	23
39	1Î±,25-Dihydroxyvitamin D₃Reduces Cerebral Amyloid-Î² Accumulation and Improves Cognition in Mouse Models of Alzheimer's Disease. Journal of Neuroscience, 2014, 34, 7091-7101.	1.7	129
40	Vitamin D Receptor Activation Down-regulates the Small Heterodimer Partner and Increases CYP7A1 to Lower Cholesterol. Gastroenterology, 2014, 146, 1048-1059.e7.	0.6	69
41	ITC Recommendations for Transporter Kinetic Parameter Estimation and Translational Modeling of Transport-Mediated PK and DDIs in Humans. Clinical Pharmacology and Therapeutics, 2013, 94, 64-79.	2.3	172
42	Temporal changes in tissue 1Î±,25-dihydroxyvitamin D₃, vitamin D receptor target genes, and calcium and PTH levels after 1,25(OH)₂D₃treatment in mice. American Journal of Physiology - Endocrinology and Metabolism, 2013, 304, E977-E989.	1.8	59
43	Comparative effects of 1Î±-hydroxyvitamin D3and 1,25-dihydroxyvitamin D3on transporters and enzymes infxr(+/+) andfxr(-/-) Mice. Biopharmaceutics and Drug Disposition, 2013, 34, n/a-n/a.	1.1	10
44	Why We Need Proper PBPK Models to Examine Intestine and Liver Oral Drug Absorption. Current Drug Metabolism, 2013, 14, 57-79.	0.7	32
45	Commentary: Theoretical Predictions of Flow Effects on Intestinal and Systemic Availability in Physiologically Based Pharmacokinetic Intestine Models: The Traditional Model, Segregated Flow Model, and Q_{Gut}Model. Drug Metabolism and Disposition, 2012, 40, 1869-1877.	1.7	28
46	1Î±,25â€Dihydroxyvitamin D₃â€liganded vitamin D receptor increases expression and transport activity of Pâ€glycoprotein in isolated rat brain capillaries and human and rat brain microvessel endothelial cells. Journal of Neurochemistry, 2012, 123, 944-953.	2.1	66
47	Evaluation of Exposure Change of Nonrenally Eliminated Drugs in Patients With Chronic Kidney Disease Using Physiologically Based Pharmacokinetic Modeling and Simulation. Journal of Clinical Pharmacology, 2012, 52, 91S-108S.	1.0	91
48	Effects of 1Î±,25-dihydroxyvitamin D3 on transport and metabolism of adefovir dipivoxil and its metabolites in Caco-2 cells. European Journal of Pharmaceutical Sciences, 2012, 46, 149-166.	1.9	26
49	Pharmacokinetics of tranexamic acid in patients undergoing cardiac surgery with use of cardiopulmonary bypass*. Anaesthesia, 2012, 67, 1242-1250.	1.8	57
50	Utility of a physiologicallyâ€“based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drugâ€“drugâ€“disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice. Biopharmaceutics and Drug Disposition, 2012, 33, 99-110.	1.1	80
51	Physiologically based pharmacokinetic (PBPK) modeling: It is here to stay!. Biopharmaceutics and Drug Disposition, 2012, 33, 47-50.	1.1	29
52	The role of lithocholic acid in the regulation of bile acid detoxication, synthesis, and transport proteins in rat and human intestine and liver slices. Toxicology in Vitro, 2011, 25, 80-90.	1.1	30
53	Transport of 5,5-diphenylbarbituric acid and its precursors and their effect on P-gp, MRP2 and CYP3A4 in Caco-2 and LS180 cells. European Journal of Pharmaceutical Sciences, 2011, 42, 19-29.	1.9	12
54	Comparative Effects of Doxercalciferol (1Î±-Hydroxyvitamin D2) Versus Calcitriol (1Î±,25-Dihydroxyvitamin) Tj ETQq0 0 0 rgBT /Overlock Sciences, 2011, 100, 1594-1604.	1.6	18

#	Article	IF	Citations
55	1Î±,25â€Dihydroxyvitamin D₃ on intestinal transporter function: studies with the rat everted intestinal sac. Biopharmaceutics and Drug Disposition, 2011, 32, 112-125.	1.1	26
56	Fraction absorbed (Fabs): Different connotations and confusion for the literature?. Biopharmaceutics and Drug Disposition, 2011, 32, 301-302.	1.1	2
57	1Î±,25-Dihydroxyvitamin D₃Up-Regulates P-Glycoprotein via the Vitamin D Receptor and Not Farnesoid X Receptor in Bothfxr(â^'/â^') andfxr(+/+) Mice and Increased Renal and Brain Efflux of Digoxin in Mice In Vivo. Journal of Pharmacology and Experimental Therapeutics, 2011, 337, 846-859.	1.3	70
58	Effects of 1Î±,25â€dihydroxyvitamin D₃ on transporters and enzymes of the rat intestine and kidney in vivo. Biopharmaceutics and Drug Disposition, 2010, 31, 91-108.	1.1	51
59	PBPK Modeling of Intestinal and Liver Enzymes and Transporters in Drug Absorption and Sequential Metabolism. Current Drug Metabolism, 2010, 11, 743-761.	0.7	52
60	Formed and preformed metabolites: facts and comparisons. Journal of Pharmacy and Pharmacology, 2010, 60, 1247-1275.	1.2	40
61	Physiologically-based pharmacokinetic modeling for absorption, transport, metabolism and excretion. Journal of Pharmacokinetics and Pharmacodynamics, 2010, 37, 591-615.	0.8	59
62	Physiological Modeling to Understand the Impact of Enzymes and Transporters on Drug and Metabolite Data and Bioavailability Estimates. Pharmaceutical Research, 2010, 27, 1237-1254.	1.7	31
63	Interplay of transporters and enzymes in the Caco2 cell monolayer: I. effect of altered apical secretion. Biopharmaceutics and Drug Disposition, 2010, 31, 215-227.	1.1	19
64	Response to Letter to the Editor on â€œPermeability, Transport, and Metabolism of Solutes in Caco-2 Cell Monolayers: A Theoretical Studyâ€• Fig. 1.. Drug Metabolism and Disposition, 2010, 38, 536-537.	1.7	1
65	Interplay of Phase II Enzymes and Transporters in Futile Cycling: Influence of Multidrug Resistance-Associated Protein 2-Mediated Excretion of Estradiol 17Î²-d-Glucuronide and Its 3-Sulfate Metabolite on Net Sulfation in Perfused TRâ^' and Wistar Rat Liver Preparations. Drug Metabolism and Disposition, 2010, 38, 769-780.	1.7	19
66	Drugâ€“Drug Interactions: What Have We Learned and Where Are We Going?. , 2010, , 701-722.		2
67	Impact of Physiological Determinants: Flow, Binding, Transporters and Enzymes on Organ and Total Body Clearances. , 2010, , 107-147.		2
68	Up-Regulation of Transporters and Enzymes by the Vitamin D Receptor Ligands, 1Î±,25-Dihydroxyvitamin D₃and Vitamin D Analogs, in the Caco-2 Cell Monolayer. Journal of Pharmacology and Experimental Therapeutics, 2009, 330, 389-402.	1.3	90
69	Disparity in Intestine Disposition between Formed and Preformed Metabolites and Implications: A Theoretical Study. Drug Metabolism and Disposition, 2009, 37, 187-202.	1.7	22
70	Safety testing of metabolites: Expectations and outcomes. Chemico-Biological Interactions, 2009, 179, 45-59.	1.7	35
71	Expression and regulation of the bile acid transporter, OSTÎ±â€OSTÎ² in rat and human intestine and liver. Biopharmaceutics and Drug Disposition, 2009, 30, 241-258.	1.1	34
72	1Î±,25â€dihydroxyvitamin D₃ triggered vitamin D receptor and farnesoid X receptorâ€like effects in rat intestine and liver in vivo. Biopharmaceutics and Drug Disposition, 2009, 30, 457-475.	1.1	58

#	Article	IF	Citations
73	Interplay of Transporters and Enzymes in Drug and Metabolite Processing. Molecular Pharmaceutics, 2009, 6, 1734-1755.	2.3	88
74	Comparison of effects of VDR versus PXR, FXR and GR ligands on the regulation of CYP3A isozymes in rat and human intestine and liver. European Journal of Pharmaceutical Sciences, 2009, 37, 115-125.	1.9	71
75	The Caco-2 cell monolayer: usefulness and limitations. Expert Opinion on Drug Metabolism and Toxicology, 2008, 4, 395-411.	1.5	367
76	A Catenary Model to Study Transport and Conjugation of Baicalein, a Bioactive Flavonoid, in the Caco-2 Cell Monolayer: Demonstration of Substrate Inhibition. Journal of Pharmacology and Experimental Therapeutics, 2008, 326, 117-126.	1.3	26
77	Role of Haptoglobin on the Uptake of Native and Î²-Chain [Trimesoyl-(Lys82)Î²-(Lys82)Î²] Cross-Linked Human Hemoglobins in Isolated Perfused Rat Livers. Drug Metabolism and Disposition, 2008, 36, 937-945.	1.7	9
78	Permeability, Transport, and Metabolism of Solutes in Caco-2 Cell Monolayers: A Theoretical Study. Drug Metabolism and Disposition, 2008, 36, 102-123.	1.7	117
79	Transporters, enzymes, and enalapril removal in a rat (CC531-induced) liver metastatic model. American Journal of Physiology - Renal Physiology, 2007, 293, G1078-G1088.	1.6	2
80	Advanced pharmacokinetic models based on organ clearance, circulatory, and fractal concepts. AAPS Journal, 2007, 9, E268-E283.	2.2	51
81	Quantitative detection of engineered nanoparticles in tissues and organs: An investigation of efficacy and linear dynamic ranges using ICP-AES. Nanobiotechnology, 2007, 3, 46-54.	1.2	20
82	An integrated approach to model hepatic drug clearance. European Journal of Pharmaceutical Sciences, 2006, 29, 215-230.	1.9	76
83	Pharmacokinetics of Nanoscale Quantum Dots: Inâ€‰Vivo Distribution, Sequestration, and Clearance in the Rat. Advanced Functional Materials, 2006, 16, 1299-1305.	7.8	328
84	Transactivation of Rat Apical Sodium-Dependent Bile Acid Transporter and Increased Bile Acid Transport by 1Î±,25-Dihydroxyvitamin D3 via the Vitamin D Receptor. Molecular Pharmacology, 2006, 69, 1913-1923.	1.0	73
85	Transport Is Not Rate-Limiting in Morphine Glucuronidation in the Single-Pass Perfused Rat Liver Preparation. Journal of Pharmacology and Experimental Therapeutics, 2006, 317, 890-900.	1.3	24
86	P-Glycoprotein and an Unstirred Water Layer Barring Digoxin Absorption in the Vascularly Perfused Rat Small Intestine Preparation: Induction Studies with Pregnenolone-16Î±-carbonitrile. Drug Metabolism and Disposition, 2006, 34, 1468-1479.	1.7	34
87	Vectorial Transport of Enalapril by Oatp1a1/Mrp2 and OATP1B1 and OATP1B3/MRP2 in Rat and Human Livers. Journal of Pharmacology and Experimental Therapeutics, 2006, 318, 395-402.	1.3	99
88	Increased Estrogen Sulfation of Estradiol 17Î²-D-Glucuronide in Metastatic Tumor Rat Livers. Journal of Pharmacology and Experimental Therapeutics, 2006, 319, 818-831.	1.3	18
89	Binding of acellular, native and cross-linked human hemoglobins to haptoglobin: enhanced distribution and clearance in the rat. American Journal of Physiology - Renal Physiology, 2005, 288, G1301-G1309.	1.6	13
90	Vascular Binding, Blood Flow, Transporter, and Enzyme Interactions on the Processing of Digoxin in Rat Liver. Journal of Pharmacology and Experimental Therapeutics, 2005, 315, 433-448.	1.3	35

#	Article	IF	Citations
91	Comparative Pharmacophore Modeling of Organic Anion Transporting Polypeptides: A Meta-Analysis of Rat Oatp1a1 and Human OATP1B1. Journal of Pharmacology and Experimental Therapeutics, 2005, 314, 533-541.	1.3	90
92	THE ROLES OF TRANSPORTERS AND ENZYMES IN HEPATIC DRUG PROCESSING. Drug Metabolism and Disposition, 2005, 33, 1-9.	1.7	104
93	Preliminary results: exploring the interactions of quantum dots with whole blood components. , 2005, 5969, 54.		0
94	Physiological Modeling of the Small Intestine in Drug Absorption. , 2004, , 3-32.		0
95	MODELING OF INTESTINAL DRUG ABSORPTION: ROLES OF TRANSPORTERS AND METABOLIC ENZYMES (FOR) Tj ETQq1 1 0.784314 rgB	1.7	227
96	INFLUENCE OF P-GLYCOPROTEIN, TRANSFER CLEARANCES, AND DRUG BINDING ON INTESTINAL METABOLISM IN CACO-2 CELL MONOLAYERS OR MEMBRANE PREPARATIONS: A THEORETICAL ANALYSIS. Drug Metabolism and Disposition, 2003, 31, 1214-1226.	1.7	32
97	Moment Analysis of Metabolic Heterogeneity: Conjugation of Benzoate with Glycine in Rat Liver Studied by Multiple Indicator Dilution Technique. Journal of Pharmacology and Experimental Therapeutics, 2003, 305, 279-289.	1.3	2
98	Retention of Transporter Activities in Cryopreserved, Isolated Rat Hepatocytes. Drug Metabolism and Disposition, 2003, 31, 447-451.	1.7	36
99	Substrate specificities of rat oatp1 and ntcp: implications for hepatic organic anion uptake. American Journal of Physiology - Renal Physiology, 2003, 285, G829-G839.	1.6	72
100	Segmental Intestinal Transporters and Metabolic Enzymes on Intestinal Drug Absorption. Drug Metabolism and Disposition, 2003, 31, 373-383.	1.7	70
101	Transport of the sulfated, amidated bile acid, sulfolithocholyltaurine, into rat hepatocytes is mediated by Oatp1 and Oatp2. Hepatology, 2002, 35, 1031-1040.	3.6	22
102	Hepatic uptake and metabolism of benzoate: a multiple indicator dilution, perfused rat liver study. American Journal of Physiology - Renal Physiology, 2001, 280, G1124-G1136.	1.6	21
103	Sulfation is rate limiting in the futile cycling between estrone and estrone sulfate in enriched periportal and perivenous rat hepatocytes. Drug Metabolism and Disposition, 2001, 29, 335-46.	1.7	21
104	Futile cycling of estrone sulfate and estrone in the recirculating perfused rat liver preparation. Journal of Pharmacology and Experimental Therapeutics, 2001, 297, 423-36.	1.3	14
105	Absorption of benzoic acid in segmental regions of the vascularly perfused rat small intestine preparation. Drug Metabolism and Disposition, 2001, 29, 1539-47.	1.7	24
106	Route-dependent metabolism of morphine in the vascularly perfused rat small intestine preparation. , 2000, 17, 291-298.		38
107	The Multiple Indicator Dilution Method and Its Utility in Risk Assessment. Environmental Health Perspectives, 2000, 108, 861.	2.8	0
108	A new physiologically based, segregated-flow model to explain route-dependent intestinal metabolism. Drug Metabolism and Disposition, 2000, 28, 224-35.	1.7	69

#	Article	IF	Citations
109	Uptake of enalapril and expression of organic anion transporting polypeptide 1 in zonal, isolated rat hepatocytes. Drug Metabolism and Disposition, 2000, 28, 801-6.	1.7	25
110	Effect of zonal transport and metabolism on hepatic removal: enalapril hydrolysis in zonal, isolated rat hepatocytes in vitro and correlation with perfusion data. Drug Metabolism and Disposition, 2000, 28, 807-13.	1.7	32
111	Differences in excretion of hippurate, as a metabolite of benzoate and as an administered species, in the single-pass isolated perfused rat kidney explained. Journal of Pharmacology and Experimental Therapeutics, 1999, 288, 597-606.	1.3	10
112	Lack of zonal uptake of estrone sulfate in enriched periportal and perivenous isolated rat hepatocytes. Drug Metabolism and Disposition, 1999, 27, 336-41.	1.7	12
113	The multiple indicator-dilution method for the study of enzyme heterogeneity in liver: theoretical basis. Drug Metabolism and Disposition, 1999, 27, 746-55.	1.7	6
114	Inhibition of esterolysis of enalapril by paraoxon increases the urinary clearance in isolated perfused rat kidney. Drug Metabolism and Disposition, 1999, 27, 931-6.	1.7	3
115	Bimolecular glutathione conjugation kinetics of ethacrynic acid in rat liver: in vitro and perfusion studies. Journal of Pharmacology and Experimental Therapeutics, 1999, 290, 1230-41.	1.3	23
116	Uptake and glutathione conjugation of ethacrynic acid and efflux of the glutathione adduct by periportal and perivenous rat hepatocytes. Journal of Pharmacology and Experimental Therapeutics, 1999, 291, 1210-9.	1.3	15
117	Application of the dispersion model for description of the outflow dilution profiles of noneliminated reference indicators in rat liver perfusion studies. Journal of Pharmacokinetics and Pharmacodynamics, 1998, 26, 163-181.	0.6	14
118	Carrier-mediated entry of 4-methylumbelliferyl sulfate: Characterization by the multiple-indicator dilution technique in perfused rat liver. Hepatology, 1998, 27, 134-146.	3.6	11
119	The modified dipeptide, enalapril, an angiotensin-converting enzyme inhibitor, is transported by the rat liver organic anion transport protein. Hepatology, 1998, 28, 1341-1346.	3.6	58
120	Hepatic uptake of hippurate: a multiple-indicator dilution, perfused rat liver study. American Journal of Physiology - Renal Physiology, 1998, 274, G10-G20.	1.6	7
121	Probing the Structure and Function of the Liver with the Multiple-Indicator Dilution Technique. , 1998, , 325-367.		3
122	Liver Cell Entry In Vivo and Enzymic Conversion. , 1998, , 297-324.		1
123	Hepatic uptake of bromosulfophthalein-glutathione in perfused Eisai hyperbilirubinemic mutant rat liver: a multiple-indicator dilution study. Journal of Pharmacology and Experimental Therapeutics, 1998, 284, 480-92.	1.3	13
124	Hepatic clearance models: comparison of the dispersion and Goresky models in outflow profiles from multiple indicator dilution rat liver studies. Drug Metabolism and Disposition, 1998, 26, 465-75.	1.7	15
125	First-Pass Effect: Significance of the Intestine for Absorption and Metabolism. Drug and Chemical Toxicology, 1997, 20, 329-344.	1.2	57
126	Organ clearance concepts: new perspectives on old principles. Journal of Pharmacokinetics and Pharmacodynamics, 1997, 25, 449-470.	0.6	72

#	Article	IF	Citations
127	Effect of flow on first-pass metabolism of drugs: single pass studies on 4-methylumbelliferone conjugation in the serially perfused rat intestine and liver preparations. Journal of Pharmacology and Experimental Therapeutics, 1997, 280, 24-31.	1.3	19
128	Uptake of sulfate conjugates by isolated rat hepatocytes. Drug Metabolism and Disposition, 1996, 24, 792-8.	1.7	16
129	Sequestered endoplasmic reticulum space for sequential metabolism of salicylamide. Coupling of hydroxylation and glucuronidation. Drug Metabolism and Disposition, 1996, 24, 821-33.	1.7	13
130	Glutathione conjugation of bromosulfophthalein in relation to hepatic glutathione content in the ratin vivo and in the perfused rat liver. Hepatology, 1995, 21, 1387-1394.	3.6	17
131	Sulfation of acetaminophen by the perfused rat liver: The effect of red blood cell carriage. Hepatology, 1995, 22, 267-282.	3.6	35
132	Carrier-mediated uptake and excretion of bromosulfophthalein-glutathione in perfused rat liver: A multiple indicator dilution study. Hepatology, 1995, 22, 1188-1207.	3.6	25
133	An understanding of flow- and diffusion-limited vs. Carrier-mediated hepatic transport: A simulation study. Journal of Pharmacokinetics and Pharmacodynamics, 1995, 23, 347-378.	0.6	8
134	Concentration-dependent metabolism of diazepam in mouse liver. Journal of Pharmacokinetics and Pharmacodynamics, 1995, 23, 243-266.	0.6	9
135	Acinar Factors in Drug Processing: Protein Binding, Futile Cycling, and Cosubstrate. Drug Metabolism Reviews, 1995, 27, 325-368.	1.5	6
136	Glutathione conjugation of bromosulfophthalein in relation to hepatic glutathione content in the rat in vivo and in the perfused rat liver. Hepatology, 1995, 21, 1387-1394.	3.6	16
137	Sulfation of acetaminophen by the perfused rat liver: the effect of red blood cell carriage. Hepatology, 1995, 22, 267-82.	3.6	9
138	Kinetics of sequential metabolism. Contribution of parallel, primary metabolic pathways to the formation of a common, secondary metabolite. Drug Metabolism and Disposition, 1995, 23, 166-77.	1.7	8
139	Salicylamide sulfate cell entry in perfused rat liver: A multiple-indicator dilution study. Hepatology, 1994, 19, 229-244.	3.6	21
140	Role of the hepatic artery in the metabolism of phenacetin and acetaminophen: An intravital microscopic and multiple-indicator dilution study in perfused rat liver. Hepatology, 1994, 20, 672-683.	3.6	31
141	Transport, binding, and metabolism of sulfate conjugates in the liver. Chemico-Biological Interactions, 1994, 92, 179-207.	1.7	28
142	Hepatic Uptake Processes. IFAC Postprint Volumes IPPV / International Federation of Automatic Control, 1994, 27, 233-237.	0.4	0
143	Pharmacokinetic Modeling of Drug Conjugates. Handbook of Experimental Pharmacology, 1994, , 257-309.	0.9	2
144	Metabolism: Scaling-up from In Vitro to Organ and Whole Body. Handbook of Experimental Pharmacology, 1994, , 101-187.	0.9	9

#	Article	IF	Citations
145	Salicylamide sulfate cell entry in perfused rat liver: A multiple-indicator dilution study. Hepatology, 1994, 19, 229-244.	3.6	2
146	Demonstration of rapid entry and a cellular binding space for salicylamide in perfused rat liver: a multiple indicator dilution study. Journal of Pharmacology and Experimental Therapeutics, 1994, 270, 285-95.	1.3	11
147	Role of the hepatic artery in the metabolism of phenacetin and acetaminophen: intravital microscopic and multiple-indicator dilution study in perfused rat liver. Hepatology, 1994, 20, 672-83.	3.6	25
148	Salicylamide sulfate cell entry in perfused rat liver: a multiple-indicator dilution study. Hepatology, 1994, 19, 229-44.	3.6	1
149	Glycine conjugation activity of benzoic acid and its acinar localization in the perfused rat liver. Journal of Pharmacology and Experimental Therapeutics, 1994, 268, 409-16.	1.3	14
150	Methods for the Quantitation of Bromosulfophthalein and Its Glutathione Conjugate in Biological Fluids. Analytical Biochemistry, 1993, 212, 28-34.	1.1	18
151	Futile cycling between 4-methylumbelliferone and its conjugates in perfused rat liver. Hepatology, 1993, 17, 838-853.	3.6	31
152	Formed and preformed metabolite excretion clearances in liver, a metabolite formation organ: Studies on enalapril and enalaprilat in the single-pass and recirculating perfused rat liver. Journal of Pharmacokinetics and Pharmacodynamics, 1993, 21, 395-422.	0.6	36
153	Combined recirculation of the rat liver and kidney: Studies with enalapril and enalaprilat. Journal of Pharmacokinetics and Pharmacodynamics, 1993, 21, 423-456.	0.6	16
154	Nonlinear protein binding and enzyme heterogeneity: Effects on hepatic drug removal. Journal of Pharmacokinetics and Pharmacodynamics, 1993, 21, 43-74.	0.6	16
155	Futile cycling between 4-methylumbelliferone and its conjugates in perfused rat liver. Hepatology, 1993, 17, 838-853.	3.6	4
156	TRANSPORT, BINDING, AND FUTILE CYCLING OF SULFATE CONJUGATES IN LIVER. Drug Metabolism and Pharmacokinetics, 1993, 8, 613-614.	0.0	0
157	Localization of glutathione conjugation activities toward bromosulfophthalein in perfused rat liver. Studies with the multiple indicator dilution technique. Drug Metabolism and Disposition, 1993, 21, 1070-8.	1.7	12
158	Effect of protein binding on 4-methylumbelliferyl sulfate desulfation kinetics in perfused rat liver. Journal of Pharmacology and Experimental Therapeutics, 1993, 266, 492-9.	1.3	14
159	Futile cycling between 4-methylumbelliferone and its conjugates in perfused rat liver. Hepatology, 1993, 17, 838-53.	3.6	5
160	Kinetics of sequential metabolism. I. Formation and metabolism of oxazepam from nordiazepam and temazepam in the perfused murine liver. Journal of Pharmacology and Experimental Therapeutics, 1993, 265, 1429-36.	1.3	12
161	Kinetics of sequential metabolism. II. Formation and metabolism of nordiazepam and oxazepam from diazepam in the perfused murine liver. Journal of Pharmacology and Experimental Therapeutics, 1993, 265, 1437-45.	1.3	10
162	Determinants of Metabolite Disposition. Annual Review of Pharmacology and Toxicology, 1992, 32, 623-669.	4.2	25

#	Article	IF	Citations
163	Enalaprilat handling by the kidney: barrier-limited cell entry. American Journal of Physiology - Renal Physiology, 1992, 263, F858-F869.	1.3	4
164	Dynamics of drug distribution. I. Role of the second and third curve moments. Journal of Pharmacokinetics and Pharmacodynamics, 1992, 20, 253-278.	0.6	32
165	A comparative investigation of hepatic clearance models: Predictions of metabolite formation and elimination. Journal of Pharmacokinetics and Pharmacodynamics, 1992, 20, 105-145.	0.6	18
166	Uptake of a protein-bound polar compound, acetaminophen sulfate, by perfused rat liver. Hepatology, 1992, 16, 173-190.	3.6	49
167	Stereoselectivity of Glutathione ConjugationIn Vivo, In the Perfused Liver and in Isolated Hepatocytes. Drug Metabolism Reviews, 1991, 23, 311-330.	1.5	5
168	D2O as a substitute for 3H2O, as a reference indicator in liver multiple-indicator dilution studies. American Journal of Physiology - Renal Physiology, 1991, 261, G929-G936.	1.6	6
169	High-performance liquid chromatographic method for the direct determination of 4-methylumbelliferone and its glucuronide and sulfate conjugates. Biomedical Applications, 1991, 563, 83-94.	1.7	19
170	Esterases for enalapril hydrolysis are concentrated in the perihepatic venous region of the rat liver. Journal of Pharmacology and Experimental Therapeutics, 1991, 257, 294-301.	1.3	14
171	A physiological model for renal drug metabolism: Enalapril esterolysis to enalaprilat in the isolated perfused rat kidney. Journal of Pharmacokinetics and Pharmacodynamics, 1990, 18, 561-587.	0.6	21
172	Physiological modeling of drug and metabolite: Disposition of oxazepam and oxazepam glucuronides in the recirculating perfused mouse liver preparation. Journal of Pharmacokinetics and Pharmacodynamics, 1990, 18, 423-448.	0.6	12
173	Transfer of enalaprilat across rat liver cell membranes is barrier limited. American Journal of Physiology - Renal Physiology, 1990, 258, G461-G475.	1.6	20
174	[14C]urea and 58Co-EDTA as reference indicators in hepatic multiple indicator dilution studies. American Journal of Physiology - Renal Physiology, 1990, 259, G32-G40.	1.6	12
175	The effect of hepatic blood flow on formation of metabolites. Drug Metabolism and Disposition, 1990, 18, 270-5.	1.7	10
176	First-pass metabolism of gentisamide: influence of intestinal metabolism on hepatic formation of conjugates. Studies in the once-through vascularly perfused rat intestine-liver preparation. Drug Metabolism and Disposition, 1990, 18, 580-7.	1.7	9
177	Estimations of intestinal and liver first-pass metabolism in vivo. Studies on gentisamide conjugation in the rat. Drug Metabolism and Disposition, 1990, 18, 588-94.	1.7	5
178	Sequential metabolism of salicylamide exclusively to gentisamide 5-glucuronide and not gentisamide sulfate conjugates in single-pass in situ perfused rat liver. Journal of Pharmacology and Experimental Therapeutics, 1990, 253, 965-73.	1.3	17
179	Effects of retrograde flow on measured blood volume, Disse space, intracellular water space and drug extraction in the perfused rat liver: characterization by the multiple indicator dilution technique. Journal of Pharmacology and Experimental Therapeutics, 1990, 254, 914-25.	1.3	9
180	Viability of the vascularly perfused, recirculating rat intestine and intestine-liver preparations. American Journal of Physiology - Renal Physiology, 1989, 257, G249-G258.	1.6	17

#	Article	IF	Citations
181	Hepatic modeling of metabolite kinetics in sequential and parallel pathways: Salicylamide and gentisamide metabolism in perfused rat liver. Journal of Pharmacokinetics and Pharmacodynamics, 1989, 17, 645-671.	0.6	27
182	The multiple-indicator dilution technique for characterization of normal and retrograde flow in once-through rat liver perfusions. Hepatology, 1989, 9, 285-296.	3.6	37
183	Renal handling of enalapril and enalaprilat: studies in the isolated red blood cell-perfused rat kidney. Journal of Pharmacology and Experimental Therapeutics, 1989, 251, 1211-22.	1.3	30
184	First-pass metabolism of salicylamide. Studies in the once-through vascularly perfused rat intestine-liver preparation. Drug Metabolism and Disposition, 1989, 17, 556-63.	1.7	20
185	Effects of perfusate flow rate on measured blood volume, disse space, intracellular water space, and drug extraction in the perfused rat liver preparation: Characterization by the multiple indicator dilution technique. Journal of Pharmacokinetics and Pharmacodynamics, 1988, 16, 595-632.	0.6	56
186	Competing pathways in drug metabolism. II. An identical, anterior enzymic distribution for 2- and 5-sulfoconjugation and a posterior localization for 5-glucuronidation of gentisamide in the rat liver. Journal of Pharmacokinetics and Pharmacodynamics, 1988, 16, 633-656.	0.6	20
187	Primary, secondary, and tertiary metabolite kinetics. Journal of Pharmacokinetics and Pharmacodynamics, 1988, 16, 493-527.	0.6	13
188	Combined hepatic arterial-portal venous and hepatic arterial-hepatic venous perfusions to probe the abundance of drug metabolizing activities: perihepatic venous O-deethylation activity for phenacetin and periportal sulfation activity for acetaminophen in the once-through rat liver preparation. Journal of Pharmacology and Experimental Therapeutics, 1988, 247, 690-700.	1.3	32
189	Competing pathways in drug metabolism. I. Effect of input concentration on the conjugation of gentisamide in the once-through in situ perfused rat liver preparation. Journal of Pharmacology and Experimental Therapeutics, 1988, 245, 614-24.	1.3	18
190	Interpretation and estimates of mean residence time with statistical moment theory. Biopharmaceutics and Drug Disposition, 1987, 8, 223-234.	1.1	7
191	High-performance liquid chromatographic method for the quantitation of salicylamide and its metabolites in biological fluids. Biomedical Applications, 1987, 420, 313-327.	1.7	4
192	Determination of diazepam and its metabolites by high-performance liquid chromatography and thin-layer chromatography. Biomedical Applications, 1987, 421, 291-307.	1.7	23
193	Competition between two enzymes for substrate removal in liver: Modulating effects due to substrate recruitment of hepatocyte activity. Journal of Pharmacokinetics and Pharmacodynamics, 1987, 15, 473-496.	0.6	35
194	Effect of diffusional barriers on drug and metabolite kinetics. Drug Metabolism and Disposition, 1987, 15, 51-8.	1.7	40
195	Metabolic Firstâ€Pass Effects. Journal of Clinical Pharmacology, 1986, 26, 580-582.	1.0	7
196	An enzyme-distributed system for lidocaine metabolism in the perfused rat liver preparation. Journal of Pharmacokinetics and Pharmacodynamics, 1986, 14, 107-130.	0.6	23
197	Absorption and metabolism of acetaminophen by the in situ perfused rat small intestine preparation. Drug Metabolism and Disposition, 1986, 14, 102-11.	1.7	32
198	Presence of a diffusional barrier on metabolite kinetics: enalaprilat as a generated versus preformed metabolite. Drug Metabolism and Disposition, 1986, 14, 513-20.	1.7	31

#	Article	IF	Citations
199	A review of metabolite kinetics. Journal of Pharmacokinetics and Pharmacodynamics, 1985, 13, 633-662.	0.6	58
200	Statistical moment theory in chemical kinetics. Analytical Chemistry, 1985, 57, 2145-2151.	3.2	15
201	Glucuronidation and sulfation in the rat in vivo. Biochemical Pharmacology, 1985, 34, 1325-1329.	2.0	39
202	Metabolism of acetaminophen and phenacetin by isolated rat hepatocytes. A system in which the spatial organization inherent in the liver is disrupted. Drug Metabolism and Disposition, 1985, 13, 42-50.	1.7	25
203	Disposition of enalapril in the perfused rat intestine-liver preparation: absorption, metabolism and first-pass effect. Journal of Pharmacology and Experimental Therapeutics, 1985, 233, 788-95.	1.3	46
204	Alteration of transit time and direction of flow to probe the heterogeneous distribution of conjugating activities for harmol in the perfused rat liver preparation. Journal of Pharmacology and Experimental Therapeutics, 1985, 234, 691-7.	1.3	23
205	Extrahepatic sulfation and glucuronidation in the rat in vivo. Biochemical Pharmacology, 1984, 33, 3081-3087.	2.0	16
206	Competition between sulphation and glucuronidation in the rat in vivo: enzyme kinetics and pharmacokinetics of conjugation. Biochemical Society Transactions, 1984, 12, 17-20.	1.6	18
207	Disposition of enalapril and its diacid metabolite, enalaprilat, in a perfused rat liver preparation. Presence of a diffusional barrier for enalaprilat into hepatocytes. Drug Metabolism and Disposition, 1984, 12, 309-13.	1.7	40
208	Inhibition of acetaminophen sulfation by 2,6-dichloro-4-nitrophenol in the perfused rat liver preparation. Lack of a compensatory increase of glucuronidation. Drug Metabolism and Disposition, 1984, 12, 323-9.	1.7	18
209	Kinetics of meperidine N-demethylation in the perfused rat liver preparation. Drug Metabolism and Disposition, 1984, 12, 698-704.	1.7	5
210	An understanding of the role of enzyme localization of the liver on metabolite kinetics: A computer simulation. Journal of Pharmacokinetics and Pharmacodynamics, 1983, 11, 451-468.	0.6	26
211	The Effect of Intercellular Distribution of Drug-Metabolizing Enzymes on the Kinetics of Stable Metabolite Formation and Elimination by Liver: First-Pass Effects. Drug Metabolism Reviews, 1983, 14, 61-76.	1.5	19
212	A commentary: methods and assumptions in the kinetic estimation of metabolite formation. Drug Metabolism and Disposition, 1983, 11, 79-84.	1.7	56
213	Normal and retrograde perfusion to probe the zonal distribution of sulfation and glucuronidation activities of harmol in the perfused rat liver preparation. Journal of Pharmacology and Experimental Therapeutics, 1983, 224, 647-53.	1.3	49
214	Kinetics of sulfation and glucuronidation of harmol in the perfused rat liver preparation. Biochemical Pharmacology, 1982, 31, 3023-3028.	2.0	22
215	Selective inhibition of sulfate conjugation in the rat. Biochemical Pharmacology, 1982, 31, 1919-1924.	2.0	23
216	Synthesis of singly 2H-, 3H-, and 14C- and doubly labeled acetaminophen, phenacetin, and p-acetanisidine. Journal of Labelled Compounds and Radiopharmaceuticals, 1982, 19, 321-329.	0.5	5

#	Article	IF	Citations
217	Metabolite kinetics: formation of acetaminophen from deuterated and nondeuterated phenacetin and acetanilide on acetaminophen sulfation kinetics in the perfused rat liver preparation. Journal of Pharmacology and Experimental Therapeutics, 1982, 222, 14-9.	1.3	10
218	Conjugation kinetics of acetaminophen by the perfused rat liver preparation. Biochemical Pharmacology, 1981, 30, 1959-1965.	2.0	23
219	Metabolite pharmacokinetics: The area under the curve of metabolite and the fractional rate of metabolism of a drug after different routes of administration for renally and hepatically cleared drugs and metabolites. Journal of Pharmacokinetics and Pharmacodynamics, 1981, 9, 477-487.	0.6	25
220	Aberrant Pharmacokinetics of harmol in the perfused rat liver preparation: sulfate and glucuronide conjugations. Journal of Pharmacology and Experimental Therapeutics, 1981, 219, 134-40.	1.3	41
221	Retrograde perfusion to probe the heterogeneous distribution of hepatic drug metabolizing enzymes in rats. Journal of Pharmacology and Experimental Therapeutics, 1981, 216, 339-46.	1.3	76
222	Metabolite pharmacokinetics: methods for simultaneous estimates of elimination rate constants of a drug and its metabolite. A commentary. Drug Metabolism and Disposition, 1980, 8, 39-43.	1.7	18
223	Sequential first-pass elimination of a metabolite derived from a precursor. Journal of Pharmacokinetics and Pharmacodynamics, 1979, 7, 275-290.	0.6	61
224	A method for the estimation of the fraction of a precursor that is converted to a metabolite in rat in vivo with phenacetin and acetaminophen. Drug Metabolism and Disposition, 1979, 7, 366-72.	1.7	13
225	A theoretical examination of the effects of gut wall metabolism, hepatic elimination, and enterohepatic recycling on estimates of bioavailability and of hepatic blood flow. Journal of Pharmacokinetics and Pharmacodynamics, 1978, 6, 355-367.	0.6	30
226	Theoretical Relationships between Area under the Curve and Route of Administration of Drugs and Their Precursors for Evaluating Sites and Pathways of Metabolism. Journal of Pharmaceutical Sciences, 1978, 67, 703-704.	1.6	20
227	Complications in the estimation of hepatic blood flow in vivo by pharmacokinetic parameters. The area under the curve after the concomitant intravenous and intraperitoneal (or intraportal) administration of acetaminophen in the rat. Drug Metabolism and Disposition, 1978, 6, 566-76.	1.7	11
228	Kinetics of metabolite formation and elimination in the perfused rat liver preparation: differences between the elimination of preformed acetaminophen and acetaminophen formed from phenacetin. Journal of Pharmacology and Experimental Therapeutics, 1978, 207, 178-94.	1.3	69
229	Theoretic aspects of pharmacokinetic drug interactions. Clinical Pharmacology and Therapeutics, 1977, 22, 623-639.	2.3	74
230	Hepatic clearance of drugs. I. Theoretical considerations of a â€œwell-stirredâ€•model and a â€œparallel tubeâ€•model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. Journal of Pharmacokinetics and Pharmacodynamics, 1977, 5, 625-653.	0.6	673
231	Hepatic clearance of drugs. II. Experimental evidence for acceptance of the â€œwell-stirredâ€•model over the â€œparallel tubeâ€•model using lidocaine in the perfused rat liverin situ preparation. Journal of Pharmacokinetics and Pharmacodynamics, 1977, 5, 655-680.	0.6	192
232	Hepatic clearance of drugs. III. Additional experimental evidence supporting the â€œwellstirredâ€•model, using metabolite (MEGX) generated from lidocaine under varying hepatic blood flow rates and linear conditions in the perfused rat liverin situ preparation. Journal of Pharmacokinetics and Pharmacodynamics, 1977, 5, 681-699.	0.6	65
233	Interaction of Drug Transporters with Excipients. , 0, , 1-31.		3
234	Interplay of Drug Transporters and Enzymes on Hepatic Drug Processing. , 0, , 709-745.		3